Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (≥16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (≥16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors UCB Biopharma

Most Recent Events

  • 26 Jun 2024 According to a UCB media release, based on clinical data from this trial, the US FDA has approved BRIVIACT (brivaracetam) and the European Commission granted the marketing authorization for BRIVIACT as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients from 16 years of age with epilepsy.
  • 05 Jul 2022 Status changed from active, no longer recruiting to completed.
  • 27 Jun 2022 Planned End Date changed from 1 Jul 2022 to 29 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top